Drugs / BMD013-T3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07657611 | Jun → Dec 2026 expected | metastatic neoplasm, neoplasm | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMD013-T3 | “Intervention 3: BMD013-T3 mRNA dry powder, 300 mcg per capsule, administered on Days 1 and 7, then weekly thereafter.” NCT07657611 ↗ |
| Modality | Messenger RNA (mRNA) | “BMD013-T3 mRNA dry powder” NCT07657611 ↗ |